title: Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
authors: Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria, Udine, Italy.
authors: Mario
authors: M
authors: Tiribelli
authors: Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
authors: Gianni
authors: G
authors: Binotto
authors: Division of Hematology, Ca' Foncello Hospital, Treviso, Italy.
authors: Elisabetta
authors: E
authors: Calistri
authors: Division of Hematology, Dell'angelo Hospital, Venezia-Mestre, Italy.
authors: Elena
authors: E
authors: Maino
authors: Department of Medicine, Section of Hematology, University of Verona, Italy.
authors: Luigi
authors: L
authors: Scaffidi
authors: Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria, Udine, Italy.
authors: Marta
authors: M
authors: Medeot
authors: Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
authors: Mitja
authors: M
authors: Nabergoj
authors: Department of Medicine, Section of Hematology, University of Verona, Italy.
authors: Achille
authors: A
authors: Ambrosetti
authors: Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
authors: Gianpietro
authors: G
authors: Semenzato
authors: Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria, Udine, Italy.
authors: Renato
authors: R
authors: Fanin
authors: Department of Medicine, Section of Hematology, University of Verona, Italy.
authors: Massimiliano
authors: M
authors: Bonifacio
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D016903:Drug Monitoring; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D015870:Gene Expression; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics*; D012306:Risk; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl